Medication adherence initiatives - Part I

Canadian Pharmacists Journal

Volumn 140, Issue 4, 2007, Pages 254-261

  McLean, William ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INSULIN; ORAL ANTIDIABETIC AGENT; THIAZIDE DIURETIC AGENT;

CLINICAL TRIAL; DRUG COST; DRUG USE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PRESCRIPTION; REVIEW; SELF REPORT; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION;

EID: 34547229136     PISSN: 17151635     EISSN: None     Source Type: Journal    
DOI: 10.3821/1913-701X(2007)140[254:MAIPI]2.0.CO;2     Document Type: Review

References (51)

1. Sabaté E, editor. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. p. 3. Available: www.who.int/chp/knowledge/publications/adherence_report/en/print.html (accessed June 7, 2007).
2. Murphy J, Coster G. Issues in patient compliance. Drugs 1997;54(6):797-800.
3. Weiss M, Britten N. What is concordance? Pharmaceutical J 2003;271:493.
4. Cramer J. ISPOR Medication Compliance and Persistence Special Interest Group. Available: www.ispor.org/sigs/medication.asp (accessed May 20, 2007).
5. Osterberger L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
6. Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates and health outcomes of medication adherence among seniors. Ann Pharmacother 2004;38:303-12.
7. Takiya LN, Peterson AM, Finley RS. Meta-analysis of interventions for medication adherence to antihypertensives. Ann Pharmacother 2004;38:1617-24.
8. Coambs RB, Jensen P, Her MH, et al. Costs of non compliance and inappropriate use of prescription medication in Canada. Toronto (ON): Publication of Health Promotion Associates; 2004.
9. Berg JS, Dischler J, Wagner DJ, et al. Medication compliance: a healthcare problem. Ann Pharmacother 1993;27:S2-S19.
10. CIHI data 2006. Available: www.cihi.ca.
11. Johnson JA, Bootman JL. Drug-related morbidity and mortality and the economic impact of pharmaceutical care. Am J Health Syst Pharm 1997;54:554-8.
12. MacKinnon NJ. Early warning systems: how vigilant pharmacists can prevent drug-related morbidity in seniors. J Pharm Pract 2002;18(8):40-4.
13. Rybacki JJ. Improving cardiovascular health in postmenopausal women by addressing medication adherence issues. J Am Pharm Assoc 2002;42:63-73.
14. Krueger KM, Felkey BG, Berger BA. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. J Am Pharm Assoc 2003;43:668-79.
15. Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease. Arch Intern Med 2005;165:2508-13.
16. Patel NC, Crismon ML, Miller AL, Johnsrud MT. Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy 2005;25(9):1242-7.
17. Breekveldt-Postma NS, Herings RM. Persistence with antihypertensives related to formulation: the case of nifedipine. Ann Pharmacother 2005;39:237-42.
18. Haynes RB, Taylor DW, Sackett DL, et al. Can simple clinical measurements detect non-compliance? J Hypertens 1980; 2:757-64.
19. Van Wijk BLG, Klungel OH, Heerdink ER, de Boer A. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Ann Pharmacother 2005;39:319-28.
20. Bluml BM, McKenney JM, Czirsky, MJ. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc 2000;40:157-65.
21. McDonald HP, Garg AX, Haynes RB. Intervention to enhance patient adherence to medication prescriptions. JAMA 2002;288:2868-79.
22. Atreja A, Bellam N, Levy SR. Strategies to enhance patient adherence: making it simple. MedGenMed 2005;7(1):4.
23. Schriber C. New devices help patients comply with medication regimen. US Pharm 2002;6:95-6.
24. Dobbels F, Van Damme-Lombaert R, Vanhaecke J, et al. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplantation 2005;9:381-90.
25. Anon. Poor medication adherence increases health care costs. PharmacoEconomics and Outcomes News 2005;480:5.
26. Sanchez RJ, Crismon ML, Barner JC, et al. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacother 2005;25(7):909-17.
27. Stroupe KT, Teal EY, Tu W, et al. Association of refill adherence and health care use among adults with hypertension in an urban health care system. Pharmacother 2006;26(6):779-89.
28. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005;118 Suppl 5A:27S-34S.
29. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with Type 2 diabetes. Diabetes Care 2004;27:2149-53.
30. Grant RW, Devita NG, Singer DE, Meigs JB. Improving adherence and reducing medication discrepancies in patients with diabetes. Ann Pharmacother 2003;37:962-9.
31. Hill-Briggs F, Gary TL, Bone LR, et al. Medication adherence and diabetes control in urban African Americans with type 2 diabetes. Health Psychol 2005;24:349-57.
32. Krass I, Taylor SJ, Smith C, Armour CL. Impact on medication use and adherence of Australian pharmacists' diabetes care services. J Am Pharm Assoc 2005;45:33-40.
33. Kilbourne AM, Good CB, Sereika SM, et al. Algorithm for assessing patients' adherence to oral hypoglycemic medication. Am J Health Syst Pharm 2005;62:198-203.
34. Walker EA, Molitch M, Kramer MK, et al. Adherence to preventive medications. Diabetes Care 2006;29:1997-2002.
35. MacLaughlin EJ, Raehl CL, Treadway AK, et al. Assessing medication adherence in the elderly. Which tools to use in clinical practice? Drugs Aging 2005;22:231-55.
36. Ryan-Woolley BM, Rees JA. Initializing concordance in frail elderly patients via a medicines organizer. Ann Pharmacother 2005;39:834-9.
37. van der Wal MH, Jaarsma T, van Velhuisen DJ. Non-compliance in patients heart failure; how can we manage it? Eur J Heart Failure 2005;7:5-17.
38. Cole JA, Norman H, Weather LB, Walker AM. Drug copayment and adherence in chronic heart failure; effect on cost and outcomes. Pharmacother 2006;26(8):1157-64.
39. Caro JJ, Salas M, Speckman JL, et al. Persistence with treatment for hypertension in actual practice. CMAJ 1999;160:31-7.
40. Grant RW, Singer DE, Meigs JB. Medication adherence before an increase in antihypertensive therapy: a cohort study using pharmacy claims data. Clin Ther 2005;27:773-81.
41. Takiya LN, Peterson AM, Finley RS. Meta-analysis of interventions for medication adherence to antihypertensives. Ann Pharmacother 2004;38:1617-24.
42. Patel RP, Taylor SD. Factors affecting medication adherence in hypertensive patients. Ann Pharmacother 2002;36:40-5.
43. Erickson SR, Ascione FJ, Kirking DM. Utility of electronic device for medication management in patients with hypertension: a pilot study. J Am Pharm Assoc 2005;45:88-91.
44. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-52.
45. Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother 2004;38:1363-8.
46. Shalansky S, Dojcinovic I. Medication specific predictors of adherence with cardiovascular regimens. Can Pharm J 2003;136(6):53.
47. Cardinal H, Monfared AAT, Dorais M, Lelorier J. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue. Can J Cardiol 2004;20:417-21.
48. Kulkarni SP, Alexander KP, Lytle B, et al. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006;151:185-91.
49. Kramer JM, Hammill B, Anstrom KJ, et al. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J 2006;152:454-60.
50. Patel BV, Leslie RS, Thiebaud P, et al. Adherence benefits in older patients of a single pill combining amlodipine and atorvastatin compared with multi-drug calcium channel blocker and statin combinations. Circulation 2006;114(18 suppl):II-829, abstract 3868.
51. Cherry SB, Hussein MA, Niuchol M, et al. Short-term clinical consequences of nonadherence in patients with hypertension and multiple risk factors. Circulation 2006;114(18 suppl):II-906, abstract 4198.